Confronto
LL-37 vs. Terlipressin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
597562-32-8
14636-12-5
Peso molecolare
4493.33 g/mol
1227.37 g/mol
Emivita
nessun dato
nessun dato
Sequenza
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESnessun dato
Meccanismo d'azione
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Terlipressin
Terlipressin is slowly converted in the body to lysine-vasopressin by cleavage of the three N-terminal glycyl residues (reservoir effect) and activates V1 receptors. The splanchnic vasoconstriction improves renal perfusion in hepatorenal syndrome.
Base di evidenze
Evidenza più alta
Studio sull'uomo
RCT sull'uomo
Studi
4
1
di cui sull'uomo
1
1
Effetti registrati
4
2
Contraddizioni aperte
1
0
Eventi avversi documentati
0
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between LL-37 and Terlipressin?
- LL-37 is classified as "Ricerca (altro)", while Terlipressin is classified as "Ricerca (altro)". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Terlipressin?
- The highest available evidence level is "Studio sull'uomo" for LL-37 and "RCT sull'uomo" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Terlipressin in Germany and the United States?
- Germania: LL-37 — Solo ricerca, Terlipressin — Su prescrizione. Stati Uniti: LL-37 — Solo ricerca, Terlipressin — Su prescrizione. These are factual summaries with source and review date on the individual pages.